ISDA

Deposition Date 2016-05-23

Release Date 2016-09-21

Last Version Date 2024-11-20

Entry Detail

PDB ID:

5K5N

Keywords:

TRANSFERASE

Title:

Crystal structure of GSK-3beta complexed with PF-04802367, a highly selective brain-penetrant kinase inhibitor

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.20 Å

R-Value Free:

0.22

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Glycogen synthase kinase-3 beta
Gene (Uniprot):GSK3B
Mutations:V28G
Chain IDs:A, B
Chain Length:370
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P49841 Pfam ID:PF00069 EC:2.7.11.26

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	modified residue

Ligand Molecules

6QH

SO4

Primary Citation

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.

Liang, S.H, Chen, J.M, Normandin, M.D, Chang, J.S, Chang, G.C, Taylor, C.K, Trapa, P, Plummer, M.S, Para, K.S, Conn, E.L, Lopresti-Morrow, L, Lanyon, L.F, Cook, J.M, Richter, K.E, Nolan, C.E, Schachter, J.B, Janat, F, Che, Y, Shanmugasundaram, V, Lefker, B.A, Enerson, B.E, Livni, E, Wang, L, Guehl, N.J, Patnaik, D, Wagner, F.F, Perlis, R, Holson, E.B, Haggarty, S.J, El Fakhri, G, Kurumbail, R.G, Vasdev, N.Show

Angew.Chem.Int.Ed.Engl. 55 9601 9605 (2016)

PMID: 27355874 DOI: 10.1002/anie.201603797

Abstact

Glycogen synthase kinase-3 (GSK-3) regulates multiple cellular processes in diabetes, oncology, and neurology. N-(3-(1H-1,2,4-triazol-1-yl)propyl)-5-(3-chloro-4-methoxyphenyl)oxazole-4-carboxamide (PF-04802367 or PF-367) has been identified as a highly potent inhibitor, which is among the most selective antagonists of GSK-3 to date. Its efficacy was demonstrated in modulation of tau phosphorylation in vitro and in vivo. Whereas the kinetics of PF-367 binding in brain tissues are too fast for an effective therapeutic agent, the pharmacokinetic profile of PF-367 is ideal for discovery of radiopharmaceuticals for GSK-3 in the central nervous system. A (11) C-isotopologue of PF-367 was synthesized and preliminary PET imaging studies in non-human primates confirmed that we have overcome the two major obstacles for imaging GSK-3, namely, reasonable brain permeability and displaceable binding.

Legend

Protein

Chemical

Disease

Primary Citation of related structures